Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
6-7-2019

Real-world treatment patterns and adverse events in metastatic
renal cell carcinoma from a large US claims database.
Sumanta Pal
Jun Gong
Shivani K Mhatre
Shih-Wen Lin
Andy Surinach

See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Nephrology Commons, and the Oncology Commons

Recommended Citation
Pal, Sumanta; Gong, Jun; Mhatre, Shivani K; Lin, Shih-Wen; Surinach, Andy; Ogale, Sarika; Vohra, Rini;
Wallen, Herschel; and George, Daniel, "Real-world treatment patterns and adverse events in metastatic
renal cell carcinoma from a large US claims database." (2019). Articles, Abstracts, and Reports. 1793.
https://digitalcommons.psjhealth.org/publications/1793

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St.
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org.

Authors
Sumanta Pal, Jun Gong, Shivani K Mhatre, Shih-Wen Lin, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel
Wallen, and Daniel George

This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/
publications/1793

Pal et al. BMC Cancer
(2019) 19:548
https://doi.org/10.1186/s12885-019-5716-z

RESEARCH ARTICLE

Open Access

Real-world treatment patterns and adverse
events in metastatic renal cell carcinoma
from a large US claims database
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Abstract
Background: Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin
kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite
treatment availability, the 5-year survival rate in patients diagnosed at the metastatic stage is only ≈ 10%. To gain
contemporary insights into RCC treatment trends that may inform clinical, scientific and payer considerations,
treatment patterns and adverse events (AEs) associated with 1 L therapy were examined in a retrospective,
longitudinal, population-based, observational study of patients with mRCC.
Methods: US administrative claims data (Truven Health MarketScan Commercial Databases) were used to assess
trends in 1 L treatment initiation in mRCC (2006–2015) and characterize patterns of individual 1 L treatments,
baseline characteristics, comorbidities and treatment-related AEs from 2011 through 2015. Outcomes were
evaluated by drug class and route of administration.
Results: Ten-year trend analysis (n = 4270) showed that TK/VEGF-directed therapy rapidly became more common
than mTOR-directed therapy, and oral treatments were favored over intravenous (IV) treatments. Overall, 1992
eligible patients initiated 1 L treatment for mRCC from 2011 through 2015: 1752 (88%) received TK/VEGF-directed
agents and 233 (12%) received mTOR-directed agents; 1674 (84%) received oral treatments, and 318 (16%) received
IV treatments. The most common 1 L treatment was sunitinib (n = 849), followed by pazopanib (n = 631),
temsirolimus (n = 157) and bevacizumab (n = 154). Patient characteristics and comorbidities, including age, diabetes
and congestive heart failure, were independent predictors of 1 L mRCC treatment choice. The three most common
potentially 1 L treatment–related AEs were nausea/vomiting (128.2 per 100 patient-years [PY]), hypertension (69 per
100 PY) and renal insufficiency (44.6 per 100 PY). A wide variety of agents were used as second-line (2 L) therapy.
Substantial latency of onset was observed for several potentially treatment-related toxicities in patients treated with
TK/VEGF- or mTOR-directed agents.
Conclusions: In the US, 1 L TK/VEGF inhibitor uptake in recent years appears largely in line with national approvals
and guidelines, with varied 2 L agent use. Although retrospective evaluation of claims data cannot assess
underlying causality, insights from these real-world RCC treatment and AE patterns will be useful in informing
medical and payer decisions.
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Background
Kidney cancer is the eighth most common cancer in the
United States [1]. Renal cell carcinoma (RCC) is the
most common type of adult kidney cancer, making up
about 90% of diagnoses [2]. Approximately 65% of patients with newly diagnosed RCC have localized disease
at the time of diagnosis, while 25 to 30% have advanced
or metastatic disease [1, 3]; approximately 20 to 40% of
patients with localized RCC will progress to metastatic
RCC (mRCC) [4]. The prognosis associated with mRCC
is poor, with a 5-year relative survival rate of approximately 8 to 12% in patients initially diagnosed with distant metastatic disease [1, 5]. Progression-free survival
(PFS) has been shown to predict overall survival (OS) in
patients with mRCC [6]; therefore, first-line (1 L) treatment for mRCC is crucial to improving outcomes.
In the last decade, several tyrosine kinase (TK) inhibitors, vascular endothelial growth factor (VEGF) inhibitors (collectively, TK/VEGF inhibitors) and mechanistic
target of rapamycin (mTOR) inhibitors have been approved in the United States for 1 L use in patients with
mRCC. These agents have notably improved efficacy [4]
compared with interferon (IFN)-α and interleukin 2 (IL-2),
the previous standards of care [7, 8]. Sunitinib and pazopanib, both multitargeted TK inhibitors that also target
VEGF, have been shown to improve objective response
rate (ORR) and PFS compared with either IFN-α or placebo, respectively [9, 10], and pazopanib was also found
to be non-inferior to sunitinib with respect to PFS, with
similar OS observed [11]. For 1 L treatment of clear cell
RCC, current National Comprehensive Cancer Network
(NCCN) guidelines recommend several treatment options with distinct mechanisms of action, including sunitinib or pazopanib as category 1 options [8]. Since the
introduction of these agents, however, data on their use in
routine clinical practice have been limited [12–14] and have
tended to focus on specific patient subgroups or selective
treatments. With the changing landscape in the 1 L treatment of mRCC, an understanding of real-world treatment
use, sequencing and associated adverse events (AEs) of
historic but widely used and recommended current
standard of care treatments is required [15, 16] and can
provide practitioner, researcher and payer insights into
the care and benefit:risk profiles of mRCC treatment.
Methods
Study objectives

The aims of this retrospective, longitudinal, populationbased, observational analysis were to (1) assess 10-year
trends in 1 L mRCC treatment initiation by drug class
and route of administration (from 2006 through 2015)
and (2) characterize the patterns of individual 1 L treatments and baseline characteristics and comorbidities of
treated patients (from 2011 through 2015). Additionally,
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in exploratory analyses, clinical factors and potentially
treatment-related AEs associated with 1 L treatments
during the latter period were assessed by drug class and
route of administration.
Study design and databases

US administrative claims data from the Truven Health
MarketScan Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination
of Benefits (Medicare) Databases were used in this study.
Cross-sectional data were used for the trend analysis,
and longitudinal data were used for all other study objectives (Fig. 1). The MarketScan Research Databases
make up the largest private-sector healthcare database in
the United States and include information from
employer-sponsored plans that provide health benefits
to over 15 million people annually, including employees,
their spouses and dependents, approximately 10% of
whom are aged ≥ 65 years. All data on treatment
utilization and medical conditions were derived from records of prescription claims for treatment and medical
claims for conditions, respectively. This study used Truven MarketScan retrospective administrative claims data.
Data were de-identified and comply with the Health Insurance Portability and Accountability Act and the 1964
Helsinki Declaration and its later amendments or comparable ethical standards. Thus, Institutional Review
Board approval was not required, and formal informed
consent was not obtained.
Patient populations and treatment definitions

For the 10-year trend analysis, patients aged ≥ 18 years
with mRCC who initiated 1 L treatment between January
1, 2006, and December 31, 2015, were included (Fig. 1a).
For analyses of treatment patterns, patient characteristics and AEs, patients aged ≥ 18 years with mRCC who
initiated 1 L treatment between January 1, 2011, and December 31, 2015 (total study period July 1, 2010 to September 30, 2016), were included (Fig. 1b). The index
date was defined as the date of 1 L treatment initiation
for mRCC, and patients were followed for a minimum of
6 months until the end of continuous enrollment. Eligibility criteria are shown in Table 1. Based on similar
mechanisms of action, agents were grouped as TK (sunitinib, sorafenib, pazopanib and axitinib)/VEGF inhibitors
(bevacizumab ± IFN-α) or mTOR-directed therapy (temsirolimus and everolimus). These agents were classified
by route of administration as oral (sunitinib, sorafenib,
pazopanib, axitinib and everolimus) or intravenous (IV;
bevacizumab ± IFN-α, temsirolimus and IL-2).
Measures

Treatment duration was defined as the number of days
from the index date to either (1) the end of the treatment
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a

b

Fig. 1 Study design. a Trend analysis. b Treatment patterns, patient characteristics and AE analysis. The study periods are indicated as durations
between closed circles. The index date (date of 1 L treatment initiation for mRCC) could occur during the index period. Patients were followed up for a
minimum of 6 months until the end of continuous enrollment. The end of 1 L treatment was defined as the last 1 L treatment claim date plus (1) the
number of days of supply of the oral treatments (last claim) or (2) the labeled cycle length for the IV treatments. Time to 2 L treatment (TT2T) was
defined as the initiation of a new 1 L therapy regimen > 30 days following the index date or restart of 1 L index treatment following a > 3-month gap

Table 1 Eligibility criteria (longitudinal analysis)
Patients,
n
Inclusion criteria
≥ 2 claims with ICD-9 code 189.0 or ICD-10 code C64.xx for malignant neoplasm of the kidney on separate dates (≥ 30 days apart)
during the index date period

77,565

First claim (ever) for a first-line mRCC agent (sunitinib, pazopanib, bevacizumab ± IFN-αa, temsirolimus, everolimus, sorafenib, axitinib,
interleukin 2) occurs during the index date period, within 30 days before the first mRCC claim and up to the end of the rolling index
period (patients with two different agents within 5 days of each other were excluded)

5813

Aged ≥ 18 years at index date

5788

Continuous enrollment eligibility 6 months pre-index and 6 months post-index dates with no gap

2565

Total no. of patients after applying all the inclusion criteria

2565

Exclusion criteria
Evidence of TCC (≥ 1 claim) from 30 days pre-index date through the entire follow-up period. TCC was identified by receipt of agent
indicated for TCC

2426

≥ 2 claims for 1 primary cancer from 6 months pre-index date through the index date (except for sites to which primary RCC commonly metastasizes, such as lung, bone, brain and liver)

1992

a
For the combination treatment with bevacizumab + IFN-α, the index date is the first occurring claim of either agent. The other drug claim must have occurred
within a period of 30 days after the first agent claim to qualify as combination treatment. TCC transitional cell (urothelial) carcinoma
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regimen (with a ≤ 3-month gap permitted) or (2) a switch
to a new treatment after 30 days following the index date.
End of 1 L treatment was calculated as the last 1 L treatment claim date plus (1) the number of days’ supply of
oral treatments (last claim) or (2) the labeled cycle length
for the IV treatments. In the event of a change to a
new treatment within 30 days of the initial index date,
followed by a subsequent refill of the second drug,
the second drug was considered the 1 L index drug
and initiation of the second drug was then defined as
the 1 L index date. Time to 2 L treatment (TT2T) was defined as the initiation of a new treatment more than 30
days following the index date or restart of 1 L index treatment following a > 3-month gap. Baseline comorbidities
were identified and incorporated into the modified DeyoCharlson Comorbidity Index (DCCI) score (including
non-cancer comorbidities), whereby a higher score reflects
a high comorbidity burden [17, 18]. Secondary metastases
were identified using ICD-9/ICD-10-CM codes and categorized as lung (197.0–197.3, C78.0-C78.3), liver (197.7,
C78.7), brain (198.3, 198.4, C79.3, C79.49), bone (198.5,
C79.5) and other sites.
Potentially treatment-related AEs were identified using
corresponding International Classification of Diseases
(ICD), Ninth Revision and ICD, Tenth Revision, Clinical
Modification codes in the administrative claims data that
occurred during the treatment duration up to 30 days
after the last 1 L drug claim. Such codes are likely associated with medical attention, though administrative
claims databases are unable to provide definitive causality. The AEs evaluated in this study were chosen from
searching the product labels for each of the drugs described, and only those that were reported to be grade 3
or 4 severity and occurring with a > 5% incidence were
included [19–25]. Additional AEs, such as diarrhea, fatigue/asthenia and hand-foot syndrome, which are commonly associated with checkpoint inhibitors, were also
included in order to provide historical estimates for the
targeted therapies (Additional file 1: Table S1).
Statistical analysis

All analyses were assessed as a function of the 1 L index
treatment, including drug class and route of administration.
Categorical variables were reported as counts and percentages, and continuous variables were reported as means with
standard deviations or medians with interquartile ranges
(Q1–Q3). For the 10-year trend analysis, the proportion of
patients receiving the index treatment by drug class and
route of administration each year was determined.
Treatment patterns were evaluated as the number and
percentage of patients receiving each 1 L treatment and
switching to the corresponding second-line (2 L) treatment, the duration of 1 L treatment and TT2T.
Kaplan-Meier methods (median, 95% CI) were used for
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the duration of 1 L treatment and TT2T. The duration
of 1 L treatment was evaluated to measure the difference
in time from the index date to the end of 1 L treatment,
with an event defined as discontinuation of 1 L treatment and switch to a 2 L treatment or discontinuation
of 1 L treatment > 3 months prior to the enrollment eligibility end date (for patients who did not switch to a 2 L
therapy). Patients who discontinued 1 L treatment within
3 months of the enrollment eligibility end date were censored at the enrollment eligibility end date. For TT2T
evaluation, an event was defined as a switch to a 2 L treatment. Patients who did not switch were censored at the
end of 1 L treatment or the end of continuous enrollment,
whichever was earlier.
Differences in baseline patient characteristics by 1 L
treatment class (TK/VEGF inhibitor vs mTOR inhibitor)
and route of administration (oral vs IV) were compared
using a univariate t test and χ2 test (or Fisher exact test
when appropriate) for continuous and categorical variables, respectively. Variables found to be statistically significant (P < 0.2) in the univariate analyses were used in
the multivariate logistic regression to model the odds of
choosing the drug class or route of administration. Irrespective of the P value in the univariate analysis, age, sex
and index year were covariates in the multivariate analysis.
AEs were reported as incidence rate per 100
patient-years (IR per 100 PY) in the total population and
in subpopulations by drug class and route of administration. IR was calculated as the number of patients with at
least one AE after the index date, divided by the total PY
at risk. If a patient did not have an AE, his/her
person-time was counted up to 30 days after the end of
1 L treatment or the end of eligibility, whichever occurred first. A washout period of 30 days prior to the
index date was applied to exclude patients with
pre-existing AEs of interest when identifying incidence
of non-chronic AEs. For chronic conditions, such as
hypertension, hypotension, hepatitis, thyroid disorders,
renal insufficiency, adrenal insufficiency and myasthenia
gravis, a 365-day washout period was applied to identify
true incident events.

Results
Ten-year trends in 1 L treatment initiation for mRCC:
cross-sectional analysis

Between 325 and 508 patients were evaluated each year
from 2006 through 2015 (Fig. 2). During the 10-year
study period, TK/VEGF-directed treatments were much
more commonly initiated than were mTOR-directed or
IL-2 treatments. Initiation of TK/VEGF-directed agents
ranged from 91 to 95.7% from 2006 through 2009,
dropped to 70.5% in 2009 and ranged from 71.5 to
84.5% between 2009 and 2015 (Fig. 2a). Starting in 2009
and extending through 2015, a downward trend for
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a

b

Fig. 2 Trends in 1 L treatment for mRCC by drug class and route of administration (2006–2015). a Trends by drug class and route of administration. TK/VEGF
inhibitors included sunitinib, pazopanib, sorafenib, axitinib and bevacizumab ± IFN-α. mTOR treatments included temsirolimus and everolimus. Orally
administered agents included sunitinib, pazopanib, sorafenib, axitinib and everolimus; IV treatments included bevacizumab ± IFN-α, temsirolimus and
interleukin 2. For the oral (blue line) vs IV (orange line) comparison, the percentage of each group sums to 100% for each year. For the TK/VEGF (grey line) vs
mTOR (yellow line) comparison, the percentage of each group may sum to < 100% because interleukin 2 was not included (accounts for < 1% of patients in
each year). b Trends by individual treatment. Trends are plotted as a single value for the entire year, and approximate timings for US FDA approvals are
indicated by diamond symbols in part b (pre-2006 approvals are shown adjacent to the y-axis). Approvals plotted include 1 L sunitinib (January 26, 2006), 1 L
pazopanib (October 19, 2009), 2 L sorafenib (December 20, 2005), 2 L axitinib (January 27, 2012), 1 L bevacizumab ± IFN-α (July 31, 2009), 1 L temsirolimus
(May 30, 2007), 2 L everolimus (March 30, 2009) and 1 L interleukin 2 (May 5, 1992). In each given year, the percentage of patients receiving each indicated
agent sums to 100%

sunitinib (61.8–35.1%) and an upward trend for pazopanib (0.4–38.9%) were observed (Fig. 2b). Initiation of
VEGF-directed therapy, consisting primarily of bevacizumab monotherapy, ranged from 3.3 to 10.1% (2006–
2015), without any distinct trend. mTOR inhibitor use,
predominantly temsirolimus, increased rapidly from
2.6% in 2008 to 21.7% in 2009 followed by a downward
trend to 8.8% in 2015. During the study period, oral
treatments were also much more common that IV
treatments, although initiation of oral treatments dropped
from 95.7 to 73.6% and that of IV treatments increased
from 4.3 to 26.4% between 2006 and 2009. After 2009, oral
initiation ranged from 76.2 to 87.3% and IV initiation
ranged from 12.7 to 23.8% (Fig. 2a).

Baseline clinical and demographic characteristics and 1 L
treatment patterns: longitudinal analysis

Overall, 1992 patients initiated 1 L treatment for mRCC
from 2011 through 2015 and were eligible for the longitudinal analysis (Table 1). The cohort had a median
(Q1–Q3) follow-up of 15.6 (10.2–25.9) months. The median age was 62 years, and the majority of patients were
male (70%) and largely from urban areas (82%). The mean
modified DCCI score was 0.7, and 63% of patients had no
reported comorbidities. The most common comorbidities
(in > 10% of patients) were diabetes (27%), chronic kidney
disease (20%), liver disease (18%) and chronic obstructive
pulmonary disease (12.6%). Characteristics of 1 L treatment subgroups are shown in Table 2.
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Table 2 Key baseline characteristics of patients initiating 1 L RCC treatment (2011–2015): drug class and administration route
Characteristic

TK/VEGF inhibitor
(n = 1752)

Age at diagnosis, median (Q1–Q3), years

62 (56–70)

Male

1220

69.6

166

71.2

1176

70.3

215

67.6

Active

568

32.4

69

29.6

563

33.6

79

24.8

Retiree

652

37.2

78

33.5

617

36.9

113

35.5

n

%

mTOR inhibitor
(n = 233)

Oral
(n = 1674)

n

n

%

62 (56–71)

IV
(n = 318)
%

61 (56–69)

n

%

64 (57–76)

Employment status

Long-term disability

11

0.6

1

0.4

8

0.5

4

1.3

Other/unknown

521

29.7

85

36.5

486

29.0

122

38.4

Northeast

327

18.7

33

14.2

303

18.1

57

17.9

North Central

467

26.7

52

22.3

451

26.9

68

21.4

South

645

36.8

104

44.6

622

37.2

131

41.2

Region

West

296

16.9

40

17.2

280

16.7

59

18.6

Unknown

17

1.0

4

1.7

18

1.1

3

0.9

Urban

1424

81.3

195

83.7

1359

81.2

267

84.0

Rural

328

18.7

38

16.3

315

18.8

51

16.0

Comprehensive

313

17.9

45

19.3

288

17.2

70

22.0

HMO

204

11.6

22

9.4

189

11.3

38

12.0

POS

130

7.4

17

7.3

120

7.2

28

8.8

PPO

926

52.9

125

53.7

896

53.5

158

49.7

Other

179

10.2

24

10.3

181

10.8

24

7.6

Commercial

1120

63.9

142

70.0

1100

65.7

169

53.1

Medicare

632

36.1

91

39.1

574

34.3

149

46.9

2011

350

20.0

78

33.5

341

20.4

88

27. 7

2012

350

20.0

62

26.6

333

19.9

80

25.2

2013

392

22.4

25

10.7

373

22.3

45

14.2

2014

327

18.7

38

16.3

309

18.5

58

18.2

2015

333

19.0

30

12.9

318

19.0

47

14.8

Metropolitan statistical area

Insurance plan type

Insurance type

Index year

Mean DCCI score (Q1–Q3)

0.70 (0–1)

0.76 (0–1)

0.66 (0–1)

0.93 (0–1)

Comorbidities
Diabetes

484

27.6

48

20.6

442

26.4

90

28.3

CKD

346

19.8

54

23.2

317

18.9

84

26.4

Liver disease

307

17.5

40

17.2

306

18.3

45

14.2

COPD

217

12.4

33

14.2

212

12.7

39

12.3

CHF

113

6.5

37

15.9

111

6.6

40

12.6

Lung

798

45.6

101

43.4

804

48.0

99

31.1

Liver

181

10.3

39

16.7

186

11.1

34

10.7

Brain

161

9.2

25

10.7

162

9.7

26

8.2

Secondary metastatic sites
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Table 2 Key baseline characteristics of patients initiating 1 L RCC treatment (2011–2015): drug class and administration route
(Continued)
Characteristic

TK/VEGF inhibitor
(n = 1752)

mTOR inhibitor
(n = 233)

Oral
(n = 1674)

IV
(n = 318)

n

%

n

%

n

%

n

%

Bone

469

26.8

85

36.5

479

28.6

76

23.9

Others

696

39.7

100

42.9

704

42.1

97

30.5

Any nephrectomy

395

22.6

47

20.2

390

23.3

53

16.7

Cytoreductive nephrectomy

380

21.7

41

17.6

377

22.5

45

14.2

Nephrectomy prior to treatment

Data are n and % unless otherwise indicated. CHF congestive heart failure, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, DCCI DeyoCharlson Comorbidity Index, HMO health maintenance organization, POS point-of-service, PPO preferred provider organization, Q quartile

Treatment patterns are included in Table 3. A total of
1752 patients (88%) received TK/VEGF inhibitor treatment, 233 (12%) received mTOR inhibitor treatment,
1674 (84%) received oral treatment and 318 (16%) received IV treatment. The most common 1 L treatment
was sunitinib (n = 849), followed by pazopanib (n = 631),
temsirolimus (n = 157) and bevacizumab (n = 149). A
total of 154 patients were treated with bevacizumab, but
only 3% (n = 5) received bevacizumab in combination
with IFN-α. Baseline characteristics by agent are shown
in Additional file 1: Tables S2 to S4.
Factors potentially associated with drug class or route
of administration were evaluated. Multivariate analyses
comparing baseline characteristics of patients treated
with TK/VEGF and mTOR inhibitors showed that patients with either baseline congestive heart failure
(CHF), secondary bone metastases or secondary liver
metastases and those who started 1 L treatment in 2011
or 2012 (vs 2015) were more likely to receive mTOR

inhibitors (Fig. 3a). Conversely, patients with baseline
diabetes were more likely to receive TK/VEGF-directed
agents than those without (Fig. 3a). In multivariate analyses comparing oral vs IV treatments, patients who had
baseline secondary lung metastases or other baseline
metastases (other than lung/liver/brain/bone) were more
likely to receive oral therapy than those who did not.
Non-retired patients and those who started 1 L treatment in 2011 or 2012 (vs 2015) were more likely to receive IV than oral treatment (Fig. 3b).
1 L treatment duration, TT2T and characterization of 2 L
treatments: longitudinal analysis

Among the 1992 patients treated with 1 L targeted
therapy, the median duration of 1 L treatment was
5.9 months (Table 3). The median duration of 1 L
TK/VEGF-directed (6.3 months) or oral (6.6 months)
treatment was longer than that of 1 L mTOR-directed
(3.9 months) or IV (3.4 months) treatment. The median

Table 3 1 L treatment patterns, duration and TT2T switch: drug class, administration route and agents
1 L treatment

Patients, n

Median duration of 1 L treatment (95% CI), monthsa

Median TT2T (95% CI), monthsa

All patients

1992

5.9 (5.5, 6.4)

9.1 (8.5, 10.0)

TK/VEGF inhibitor

1752

6.3 (5.8, 6.7)

9.8 (8.9, 10.4)

mTOR inhibitor

233

3.9 (3.4, 4.8)

6.0 (4.6, 7.1)

Oral

1674

6.6 (6.0, 7.3)

9.4 (8.6, 10.2)

IV

318

3.4 (2.7, 3.9)

7.3 (6.0, 9.9)

849

6.5 (5.9, 7.6)

9.4 (8.5, 10.3)

Class

Route of administration

Agent
Sunitinib (TK; oral)

a

Sorafenib (TK; oral)

62

4.7 (3.3, 9.8)

8.4 (4.8, 12.6)

Pazopanib (TK; oral)

631

7.0 (6.0, 8.0)

9.3 (8.2, 10.6)

Axitinib (TK; oral)

56

12.0 (7.4, 18.8)

14.4 (7.7, 22.3)

Bevacizumab (VEGF; IV)

149

2.8 (1.8, 4.4)

22.5 (11.7, NR)

Everolimus (mTOR; oral)

76

4.0 (3.2, 6.1)

8.0 (3.6, 11.3)

Temsirolimus (mTOR; IV)

157

3.9 (3.0, 4.8)

5.7 (4.3, 6.7)

Kaplan-Meier methods were used. NR not reached
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a

b

Fig. 3 Multivariate analysis. a Odds of receiving 1 L mTOR vs TK/VEGF inhibitors. b Odds of receiving IV vs orally administered treatment. Only
variables found to be significant are plotted. Other variables in the multivariate analysis for the comparison of TK/VEGF inhibitor treatment vs
mTOR inhibitor treatment were not significantly different (age, sex, index years 2013 and 2014 vs 2015, DCCI and nephrectomy). Other variables
in the multivariate analysis for the comparison of oral vs IV administration that did not reach statistical significance were sex, employment status
(active and long-term disability vs retiree), insurance type, DCCI, index years 2013 and 2014 vs 2015 and nephrectomy)

TT2T was 9.1 months (Table 3). Among the oral agents,
axitinib had the longest median treatment duration
(12.0 months) and median TT2T (14.4 months); everolimus had the shortest median treatment duration (4.0
months) and median TT2T (8.0 months). Among the IV
agents, the median treatment durations of temsirolimus
and bevacizumab were 3.9 and 2.8 months, respectively.
The median TT2T was 5.7 months for temsirolimus and
22.5 months for bevacizumab (Table 3). The flow of
treatment across lines of therapy is shown in Fig. 4. Of
the 1992 patients who received 1 L treatment, 52.8%
(n = 1052) received a 2 L treatment. The median
follow-up durations in patients who did and did not

receive 2 L treatment were 17.2 and 14.4 months, respectively. Everolimus was the 2 L drug of choice (15.2% of all
1992 evaluated patients), followed by axitinib (10.7%)
and nivolumab (4.6%). Overall, 28% of all patients received 2 L TK/VEGF-directed therapy, and 20% received
2 L mTOR-targeted therapy. Forty-one percent of patients received oral 2 L therapy, and 12% received IV 2 L
therapy (including nivolumab).
IR and time to potentially treatment-related AEs:
longitudinal analysis

The three most common, potentially treatment-related
AEs occurring during or up to 30 days after 1 L
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Fig. 4 1 L to 2 L treatment flow in patients with mRCC in the Truven Health MarketScan databases. Possible reasons for patients not receiving 2 L
treatment include still being on 1 L treatment, no requirement for 2 L treatment, refusal of treatment and death, although these cannot be
reliably obtained from the claims database

treatment were nausea/vomiting (127.2 per 100 PY),
hypertension (69.1 per 100 PY) and renal insufficiency
(44.5 per 100 PY) (Table 4). In addition to nausea/vomiting and renal insufficiency, hypertension (in patients
who received oral treatment and those treated with TK/
VEGF inhibitors) and anemia (in patients who received
IV treatment and those treated with mTOR-directed
therapy) were among the four most common AEs when
evaluated separately by treatment categories.
Based on time between the claims indicating the initiation of a drug and the initial AE that may have required
medical attention, substantial latency of onset (median
time to first AE claim) was observed for several potentially treatment-related toxicities in patients treated with
1 L TK/VEGF-directed treatment, including nausea/
vomiting (21 days), fatigue/asthenia (72 days), thyroid
disorders (133 days), abdominal pain (99 days), diarrhea
(108 days), pneumonitis (83 days), hepatitis (154 days),
adrenal insufficiency (119 days), neutropenia (110 days)
and colitis (97 days) (Table 5).

Discussion
As the number of 1 L and 2 L treatment options for
mRCC increases, and the role of effective sequencing of
agents evolves, a thorough understanding of the

treatment patterns and AE profiles of each drug class in
the real-world setting will be critical to providing medical benchmarks, assessing adherence to guidelines and
informing benefit:risk decisions in selecting the appropriate mRCC treatment. This retrospective, claims-based
analysis evaluated treatment patterns and AEs among a
large, real-world, US population of patients with mRCC.
A cross-sectional analysis was performed to better
understand the patterns of 1 L treatment initiation over
a 10-year period, and a longitudinal analysis provided
information of treatment choice, baseline correlates
and associated AEs in patients treated in routine
medical practice.
The cross-sectional trend analysis demonstrated that
1 L treatment initiation patterns for mRCC generally
reflected the US Food and Drug Administration approvals and NCCN treatment guidelines, with a few exceptions. The rapid uptake of the TK-targeting agents
sunitinib (approved in 2006) and pazopanib (approved in
2009) was noted, establishing TK/VEGF-directed treatment as the most widely prescribed drug class initiated
during the study period. Throughout the study period,
oral treatments were also more commonly used than IV
treatments. These patterns of TK/VEGF inhibitors and
oral agents were also recapitulated in the longitudinal
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Table 4 AE IRs in patients with mRCC by drug class and administration route
Potentially treatment-related
AEs during or < 30 days after
1 L treatmenta

All patients
(N = 1992)

TK/VEGF inhibitor
(n = 1752)

mTOR inhibitor
(n = 233)

Oral
(n = 1674)

IV
(n = 318)

IR per 100 PYa
(Poisson 95% CI)

IR per 100 PYa
(Poisson 95% CI)

IR per 100 PYa
(Poisson 95% CI)

IR per 100 PYa
(Poisson 95% CI)

IR per 100 PYa
(Poisson 95% CI)

Fatigue/asthenia

39.8
(36.3, 43.6)

38.2
(34.5, 42.0)

55.2
(41.7, 70.5)

38.7
(34.9, 42.6)

49.3
(37.8, 62.3)

Hypertension

69.1
(61.3, 77.4)

71.7
(63.3, 80.7)

47.8
(29.2, 71.0)

70.2
(61.9, 79.0)

59.2
(37.9, 85.2)

Diarrhea

28.5
(25.6, 31.6)

29.9
(26.7, 33.2)

13.1
(7.3, 20.5)

30.7
(27.5, 34.1)

13.2
8.0, 19.5)

Hand-foot syndrome

4.1
(3.1, 5.2)

4.0
(3.0, 5.2)

3.1
(0.9, 6.9)

4.0
(3.0, 5.2)

4.4
(1.8, 8.3)

Dyspnea

37.6
(34.1, 41.2)

34.7
(31.3, 38.4)

69.6
(53.4, 88.0)

35.9
(32.3, 39.6)

51.7
(39.9, 65.0)

Nausea/vomiting

127.2
(119.0, 135.6)

114.2
(106.3, 122.4)

364.5
(304.6, 429.8)

119.1
(110.8, 127.6)

209.7
(175.6, 246.8)

Back pain

19.9
(17.5, 22.4)

20.3
(17.8, 23.0)

16.2
(9.7, 24.2)

19.8
(17.3, 22.5)

20.8
(14.0, 28.9)

Pain in extremity/limb discomfort

27.8
(24.9, 30.8)

26.6
(23.6, 29.7)

40.9
(29.6, 54.0)

27.1
(24.1, 30.3)

33.0
(24.1, 43.4)

Abdominal pain

31.2
(28.1, 34.5)

30.6
(27.4, 34.0)

35.8
(25.1, 48.4)

32.0
(28.7, 35.6)

25.0
(17.3, 34.1)

Anemia

40.3
(36.6, 44.1)

35.4
(31.8, 39.1)

100.3
(79.1, 123.9)

37.9
(34.1, 41.8)

61.6
(48.0, 76.9)

Hypophosphatemia

1.7
(1.1, 2.5)

1.5
(0.9, 2.2)

2.3
(0.5, 5.6)

1.5
(0.9, 2.3)

3.1
(1.0, 6.4)

Neutropenia

3.9
(3.0, 5.0)

4.2
(3.1,5.3)

1.6
(0.2, 4.3)

4.2
(3.1, 5.4)

1.9
(0.4, 4.5)

Lymphopenia

0.2
(0.0, 0.5)

0.1
(0.0, 0.3)

1.6
(0.2, 4.3)

0.2
(0.0, 0.4)

0.6
(0.0, 2.3)

Hypotension

7.7
(6.3, 9.3)

7.6
(6.2, 9.2)

7.2
(3.3, 12.7)

7.6
(6.1, 9.3)

8.6
(4.6, 13.8)

Proteinuria

5.2
(4.1, 6.5)

5.0
(3.9, 6.3)

7.3
(3.4, 12.9)

4.7
(3.6, 5.9)

9.8
(5.5, 15.4)

Thrombocytopenia

3.0
(2.2, 3.9)

3.0
(2.2, 4.1)

2.3
(0.5, 5.6)

3.1
(2.2, 4.1)

1.9
(0.4, 4.5)

Hepatitis

9.3
(7.7, 11.1)

9.1
(7.5, 11.0)

11.0
(5.7, 18.1)

9.7
(7.9, 11.6)

6.3
(2.9, 11.0)

Thyroid disorders

21.2
(18.6, 24.0)

21.9
(19.1, 24.9)

14.9
(8.5, 23.0)

22.9
(20.0, 26.0)

9.5
(5.0, 15.3)

Renal insufficiency

44.5
(38.9, 50.5)

42.3
(36.6, 48.4)

60.8
(38.9, 87.4)

43.0
(37.2, 49.3)

58.3
(39.0, 81.3)

Adrenal insufficiency

6.3
(5.0, 7.7)

5.8
(4.5, 7.2)

10.4
(5.4, 17.0)

5.9
(4.6, 7.4)

9.1
(4.8, 14.6)

Pneumonitis

27.3
(24.4, 30.2)

24.6
(21.8, 27.6)

56.2
(42.4, 71.8)

25.2
(22.4, 28.3)

43.6
(33.3, 55.3)

Colitis

0.5
(0.2, 0.9)

0.5
(0.2, 0.9)

0.8
(0.0, 2.9)

0.4
(0.1, 0.8)

1.3
(0.2, 3.5)

Guillain-Barré syndrome

0.1
(0.0, 0.3)

0.1
(0.0, 0.3)

0

0.1
(0.0, 0.3)

0

Meningoencephalitis

0.5
(0.2, 0.9)

0.5
(0.2, 1.0)

0

0.5
(0.2, 0.9)

0.6
(0.0, 2.3)

Myasthenia gravis

0

0

0

0

0

Rash

10.1
(8.5, 11.9)

9.5
(7.9, 11.3)

14.3
(8.4, 21.9)

9.9
(8.2, 11.7)

11.9
(7.1, 18.0)

a

Washout period of 30 days prior to the index date was applied when identifying incidence events for all AEs, except for chronic conditions, where a
365-day washout period was applied. If a patient did not have an event, their person-time was counted up to 30 days after the end of first-line
treatment or the end of eligibility, whichever occurred first
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Table 5 Time to onset of AEs by drug class and route of administration
Adverse event

All patients
(N = 1992)

TK/VEGF inhibitor
(n = 1752)

mTOR inhibitor
(n = 233)

Oral
(n = 1674)

IV
(n = 318)

Median, days
(Q1–Q3)

Median, days
(Q1–Q3)

Median, days
(Q1–Q3)

Median, days
(Q1–Q3)

Median, days
(Q1–Q3)

Fatigue/asthenia

72.0
(29.0, 157.0)

74.0
(28.0, 168.0)

63.0
(35.5, 119.0)

74.0
(28.0, 165.0)

58.5
(29.0, 118.0)

Hypertension

72.0
(28.0, 156.0)

70.0
(28.0, 151.0)

116.5
(42.0, 240.5)

72.0
(29.0, 163.0)

76.5
(11.5, 138.5)

Diarrhea

108.0
(45.0, 211.0)

111.0
(48.5, 215.5)

46.0
(25.0, 194.0)

110.0
(48.0, 214.0)

46.5
(21.5, 194.5)

Hand-foot syndrome

93.5
(43.0, 218.0)

109.0
(54.0, 231.5.0)

30.0
(20.5, 53.0)

112.0
(57.0, 241.0)

30.0
(10.0, 33.0)

Dyspnea

88.0
(28.0, 210.0)

94.0
(29.0, 227.0)

68.5
(23.0, 156.0)

95.0
(31.0, 226.0)

52.0
(20.0, 146.0)

Nausea/vomiting

21.0
(4.0, 78.0)

27.0
(7.0, 89.0)

0

28.0
(8.0, 90.0)

0

Back pain

90.0
(31.0, 198.0)

90.5
(34.0, 197.50)

89.0
(22.0, 287.0)

93.0
(34.0, 198.0)

75.0
(20.0, 196.0)

Pain in extremity/limb discomfort

112.0
(46.0, 238.0)

113.0
(44.0, 238.0)

95.0
(48.0, 240.0)

113.0
(46.5, 246.0)

83.0
(44.0, 165.0)

Abdominal pain

98.5
(35.0, 226.5)

104.5
(36.0, 229.0)

87.0
(32.5, 195.0)

104.5
(37.0, 229.0)

63.5
(30.0, 176.0)

Anemia

85.0
(32.5, 183.5)

93.0
(35.0, 200.0)

66.0
(26.0, 132.0)

93.5
(35.0, 201.0)

64.5
(18.0, 118.0)

Hypophosphatemia

100.0
(56.0, 138.0)

102.0
(60.0, 136.5)

299.0
(43.0, 498.0)

110.0
(60.0, 146.0)

43.0
(9.0, 104.0)

Neutropenia

110.0
(47.5, 242.5)

117.0
(48.0, 245.0)

37.5
(19.0, 56.0)

115.0
(48.0, 240.0)

56.0
(19.0, 465.0)

Lymphopenia

108.0
(95.0, 136.0)

95.0
(95.0, 95.0)

122.0
(108.0, 136.0)

115.5
(95.0, 136.0)

108.0
(108.0, 108.0)

Hypotension

105.0
(42.0, 222.0)

117.5
(44.0, 239.0)

58.0
(51.0, 179.0)

111.0
(43.0, 230.0)

56.0
(41.0, 191.0)

Proteinuria

80.5
(29.0, 245.0)

84.0
(30.0, 235.0)

56.0
(26.0, 257.0)

108.0
(41.0, 336.0)

30.0
(20.0, 84.0)

Thrombocytopenia

97.0
(50.0, 188.0)

93.5
(48.5, 194.0)

112.0
(52.0, 140.0)

87.0
(48.5, 187.0)

140.0
(112.0, 256.0)

Hepatitis

154.0
(71.0, 256.0)

148.0
(71.0, 253.0)

209.0
(128.0, 326.0)

150.5
(71.0, 256.0)

190.0
(166.0, 234.0)

Thyroid disorders

133.0
(75.0, 256.0)

134.0
(79.0, 259.0)

91.0
(55.0, 196.0)

133.5
(79.0, 259.0)

131.0
(62.0, 175.0)

Renal insufficiency

94.0
(33.0, 217.0)

95.0
(39.5, 225.5)

90.5
(18.0, 62.5)

97.0
(41.0, 231.0)

61.0
(14.0, 133.0)

Adrenal insufficiency

119.0
(69.0, 213.0)

108.0
(67.0, 227.0)

147.0
(118.0, 200.0)

110.0
(70.0, 218.0)

132.0
(4.0, 201.0)

Pneumonitis

83.0
(29.0, 209.0)

87.0
(31.0, 223.0)

73.5
(21.5, 155.5)

90.0
(31.0, 223.0)

68.5
(19.5, 150.5)

Colitis

97.0
(43.0, 139.0)

101.5
(66.0, 139.0)

0

106.0
(97.0, 139.0)

21.5
(0.0, 43.0)

Guillain-Barré syndrome

52.0
(52.0, 52.0)

52.0
(52.0, 52.0)

0

52.0
(52.0, 52.0)

0

Meningoencephalitis

122.0
(75.0, 159.0)

122.0
(75.0, 159.0)

0

112.0
(75.0, 159.0)

122.0
(122.0, 122.0

Myasthenia gravis

0

0

0

0

0

Rash

79.0
(37.5, 214.0)

83.0
(44.0, 220.0)

55.0
(23.0, 149.0)

82.5
(47.0, 213.0)

28.0
(10.0, 224.0)
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analysis. These findings are consistent with those from
studies detailing the widespread use of TK inhibitors
[26], and the less frequent use of sorafenib and axitinib
in the 1 L setting is also consistent with NCCN recommendations for these TK inhibitors [8]. Of note was the
finding that the use of bevacizumab as monotherapy was
more prevalent than as combination therapy with IFN-α.
These findings suggest that increased costs and
IFN-related toxicities may render bevacizumab more attractive as monotherapy than as combination therapy
with IFN [27]. Moreover, Phase II data support the use of
bevacizumab as 1 L treatment and salvage therapy [28,
29]. Additionally, a considerable number of patients received everolimus in the 1 L setting despite the lack of indication in this setting, which reflects the wide variability
seen in provider preference and clinical experience.
Provider preferences, patient history and known toxicities associated with drug classes may drive 1 L treatment choice, although it is difficult to ascertain from
claims data which characteristics influenced the specific
choices of mRCC treatment. In this study, CHF and a
DCCI score ≥ 4 were independent predictors of IV treatment choice, while patients with lung metastases were
less likely to receive IV treatment than were those without lung metastases. Patients with diabetes were less
likely to receive mTOR-directed therapy, while patients
with comorbid CHF, liver metastases or bone metastases
were more likely to receive mTOR-directed therapy.
These data are in agreement with the known cardiotoxicity associated with both sunitinib and pazopanib [23,
25], such as cardiac dysfunction (sunitinib, 11% frequency; pazopanib, 13%) and myocardial infarction/ischemia (sunitinib, 4% frequency; pazopanib, 2%) [11].
Similarly, a preference for TK/VEGF inhibitors in those
with diabetes can be explained by the fact that hyperglycemia is a well-known AE associated with mTOR
inhibitors (observed in 26% of patients treated with temsirolimus [30] and 50% treated with everolimus [31]) .
Duration of treatment also varies by agent and may influence treatment choice. Median duration of TK/
VEGF-directed treatment was much longer than that of
mTOR-directed treatment (6.3 and 3.9 months); similarly, oral treatment duration was nearly twice that of IV
treatment (6.6 and 3.4 months). The median durations
of sunitinib and pazopanib treatment were similar to
each other (6.5 and 7.0 months, respectively), but were
longer than those of sorafenib (4.7 months), everolimus
(4.0 months), and temsirolimus (3.9 months). Reported
results of real-world studies are mixed. For example, the
observed sunitinib and sorafenib treatment durations
were similar to those reported by Feinberg et al. (5.9 and
5.5 months, respectively) [32] and only slightly longer
than those reported by Miller et al. (5.6 and 5.3 months,
respectively), who also reported durations of 5.3 months
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for pazopanib and 4.5 months for everolimus [14]. However, these durations are slightly longer than those reported by Hess et al. (3.2 and 4.0 months, respectively;
2.6 months for temsirolimus) [33] and Vogelzang et al.
(sunitinib, 4.1 months; pazopanib 4.8 months) [15]. However, it should be noted that direct cross-study comparisons are not possible based on different analysis
methods and populations. Treatment durations reported
in the randomized clinical trial setting are also sometimes mixed and are not dissimilar to the results from
this study. For instance, Phase III data have shown 1 L
median treatment durations of 7.6 and 8.0 months, respectively, for TK inhibitors sunitinib and pazopanib
[11] and 3.9 months for the mTOR inhibitor temsirolimus [30]. Collectively, these data suggest that there are
potential differences in patient selection, outcomes
measurement and patient preference between real-world
data studies and randomized clinical trials that could
have implications for future clinical trial design. These
differences may reflect the difficulty in (1) maintaining
adequate dosing with these relatively toxic agents and
(2) reproducing clinical trial results in the real-world setting for mRCC.
Potential differences in toxicities between the 1 L treatments in this study vs those previously seen were also
evaluated, and it was noted that the most common AEs
associated with each drug class were generally consistent
with previously reported results [34–37] and with the
product labels [19–25]. Notably, however, substantial latency of onset was observed for several potentially
treatment-related toxicities in patients treated with both
TK/VEGF- and mTOR-inhibitor classes, which was
much different in clinical practice (i.e., onset of fatigue,
hypertension and hepatic dysfunction generally occurs
quickly). AE latency in the database may be due to capture of only the toxicities that generate a medical claim
and may suggest that the toxicities that are observed
early on may not receive medical care in clinical practice. There were also AEs potentially associated with
checkpoint inhibitors. The latency of these AEs was similar to that observed with checkpoint inhibitors [38, 39].
These results suggest that attributing toxicities to TK/
VEGF-directed therapies vs checkpoint inhibitors, when
used in combination, may be challenging due to overlapping toxicities.
In contrast to the 1 L treatment data, 2 L treatment
data were less defined. In this study, nearly half of all patients did not have evidence of receiving 2 L treatment
(47% [n = 940]); however, there is no reliable way to determine the reasons for this from a claims database. Patients who did not receive 2 L therapy in this study may
either still be receiving 1 L targeted therapy (and were
not captured in the study due to the follow-up period
ending) or have attained sustained remission, died before
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receiving 2 L therapy, refused 2 L treatment or did not
receive 2 L therapy for unknown reasons. Consistent
with other studies, most patients treated with a 1 L oral
TK inhibitor who received 2 L therapy were switched to
2 L mTOR-directed treatment, primarily everolimus
[26]; 2 L treatment choice warrants further investigation.
This study had several strengths and limitations.
Strengths include the large number of 1 L–treated patients with mRCC over time, including those treated
with TK/VEGF- or mTOR-directed therapy. The use of
the MarketScan databases also provided strength to this
study due to the inclusion of the full continuum of care
in all inpatient and outpatient settings, as well as retail
and specialty pharmacies, and the longitudinal tracking
of patient information. However, the MarketScan databases also have limitations, as they are inherently restricted to insured patients and provide limited social
background and demographic data. Secondary metastasis codes were not required for identification of patients
with mRCC since the 1 L treatments are approved in the
metastatic setting only and to avoid exclusion of eligible
patients due to potential underreporting of secondary
metastasis codes. However, the study could have included patients who received the treatments off-label in
the adjuvant/neoadjuvant setting. Further, administrative
claims-based data are prone to coding and data entry errors. Potential underreporting of secondary metastasis
and baseline comorbidities may have affected the point
estimates in the multivariate models, and the distribution of these variables may not be representative of the
RCC population in clinical practice. Moreover, only AEs
of sufficient severity to prompt medical attention and
generate a claim could be identified, which may have led
to underreported IRs. It was also not possible to discern
from the claims data whether an AE was reported due
to a drug reaction, RCC progression or other cause, nor
was it possible to know the severity/grade of the AE.
Further, it is unknown from the claims data whether 2 L
treatment was received due to toxicity or disease progression. In this study, the treatment duration end date
was calculated by adding the days’ supply of oral treatment and cycle length for IV treatment. Since most patients receive their oral drug supply 1 to 3 months in
advance, the treatment duration for oral medications
may have been overestimated. Additionally, the proportion of patients who switched treatment may have been
underreported due to the limited follow-up in this study
(median of ≈ 16 months after the index date). However,
this median follow-up may be of limited concern considering the low survival rates in this patient population [40, 41].
Lastly, recent approvals (e.g., cabozantinib and nivolumab ±
ipilimumab) and treatment recommendations were not captured given that these agents were not approved during the
period covered by the analysis [42–44].
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Conclusions
In this retrospective, claims-based study of patients with
mRCC in the Truven Health MarketScan databases,
10-year prescribing trends showed the transition from
cytokine-based treatment to targeted agents and a similar shift from IV to oral agents. Observed 1 L treatment
patterns generally suggested good adherence to NCCN
guideline recommendations, although treatment durations across the literature appear variable. In all patients
and those treated with TK/VEGF- and mTOR-directed
1 L treatment, the three most common AEs were hypertension, nausea/vomiting and renal insufficiency. The 2 L
treatments included a wide variety of agents for mRCC.
With new agents and combinations (e.g., checkpoint inhibitor therapy) emerging following this study period
(through 2016), these data will be useful in providing
medical benchmarks for contemporary mRCC therapy.
Additional file
Additional file 1: Table S1. Listing of AEs included for analysis, with
ICD-9/ICD-10-CM codes. Table S2. Baseline characteristics by TK inhibitor
type. Table S3. Baseline characteristics by VEGF inhibitor type. Table S4.
Baseline characteristics by mTOR inhibitor type. (DOCX 71 kb)
Abbreviations
1 L: First-line; 2 L: Second-line; AE: Adverse event; CHF: Congestive heart
failure; DCCI: Deyo-Charlson Comorbidity Index; IFN: Interferon; IL: Interleukin;
IR: Incidence rate; IV: Intravenous; mRCC: Metastatic renal cell carcinoma;
mTOR: Mechanistic target of rapamycin kinase; NCCN: National
Comprehensive Cancer Network; ORR: Objective response rate; OS: Overall
survival; PFS: Progression-free survival; PY: Patient-years; Q: Quartile;
RCC: Renal cell carcinoma; TK: Tyrosine kinase; TT2T: Time to 2 L treatment;
VEGF: Vascular endothelial growth factor
Acknowledgements
Medical writing assistance for this manuscript was provided by Ashley J.
Pratt, PhD, of Health Interactions, Inc. (San Francisco, CA), and was funded by
F. Hoffmann-La Roche, Ltd.
Funding
This study was sponsored by F. Hoffmann-La Roche, Ltd. The sponsor was involved in the design of the study, the collection, analysis, and interpretation
of data as well as final approval of the manuscript. Medical writing assistance
was provided by a professional medical writer funded by the sponsor.
Availability of data and materials
The data that support the findings of this study are available from Truven
Health Analytics® (part of the IBM Watson Health business), but restrictions
apply to the availability of these data, which were used under license for the
current study.
Authors’ contributions
SP, SKM, S-WL, SO and DG contributed to study design. AS contributed to
data analysis. All authors contributed to the interpretation of results and
preparation of the manuscript, gave approval to submit the manuscript and
agree to be accountable for the work.
Authors’ information
Not applicable
Ethics approval and consent to participate
This study used Truven MarketScan retrospective administrative claims data.
Data were de-identified and comply with the Health Insurance Portability

Pal et al. BMC Cancer

(2019) 19:548

and Accountability Act and the 1964 Helsinki Declaration and its later
amendments or comparable ethical standards. Thus, Institutional Review
Board approval was not required, and formal informed consent was not
obtained.
Consent for publication
Not applicable.
Competing interests
SP reports honoraria and a consulting/advisory role with Novartis, Astellas,
Aveo, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Myriad Pharmaceuticals, Pfizer
and Roche/Genentech and honoraria and research funding from Medivation.
AS is employed by Genesis Research and reports a consulting/advisory role
with Roche/Genentech. SKM, SW and SO are employees of Genentech, Inc.
and own Roche stock. DG reports consulting/advisory roles with Astellas,
AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Exelixis, Genentech/Roche,
Innocrin, Janssen, Myovant, Pfizer and Sanofi and received research funding
from Astellas, Bayer, Innocrin, Janssen, Novartis and Pfizer. HW is a former
employee of Roche/Genentech. RV was a paid intern at Roche/Genentech at
the time of the study. JG declares that he has no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1
Department of Medical Oncology and Experimental Therapeutics, City of
Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010,
USA. 2Department of Hematology/Oncology, City of Hope National Medical
Center, 1500 East Duarte Road, Duarte, CA 91010, USA. 3Real World Data
Science (Oncology), Genentech, Inc, 1 DNA Way, MS 352B, South San
Francisco, CA 94080, USA. 4Genesis Research, 5 Marine View Plaza, Hoboken,
NJ 07030, USA. 5US Medical Affairs, Genentech, Inc, 1 DNA Way, MS 352B,
South San Francisco, CA 94080, USA. 6School of Pharmacy, West Virginia
University, P.O. Box 9500, Morgantown, WV 26506, USA. 7Oncology and
Hematology Care Clinic, Providence Cancer Center, 4805 NE Glisan Street,
Suite 6N40, Portland, OR 97213, USA. 8Department of Medicine, Medical
Oncology, Duke University School of Medicine, Box 103861, Durham, NC
27710, USA.
Received: 23 January 2018 Accepted: 14 May 2019

References
1. National Cancer Institute. SEER Cancer Stat Facts: Kidney and Renal
Pelvis Cancer. https://seer.cancer.gov/statfacts/html/kidrp.html. Accessed
3 Feb 2019.
2. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell
carcinoma. Eur Urol. 2011;60(4):615–21.
3. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and
socioeconomic burden of metastatic renal cell carcinoma (mRCC): a
literature review. Cancer Treat Rev. 2008;34(3):193–205.
4. Pal SK, Ghate SR, Li N, et al. Real-world survival outcomes and prognostic
factors among patients receiving first targeted therapy for advanced renal
cell carcinoma: a SEER-Medicare database analysis. Clin Genitourin Cancer.
2017;15(4):e573–82.
5. American Cancer Society. Survival rates for kidney cancer by stage. https://
www.cancer.org/cancer/kidney-cancer/detection-diagnosis-staging/survivalrates.html. Accessed 3 Feb 2019.
6. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor
of overall survival in metastatic renal cell carcinoma treated with
contemporary targeted therapy. Cancer. 2011;117(12):2637–42.
7. Sun M, Larcher A, Karakiewicz PI. Optimal first-line and second-line
treatments for metastatic renal cell carcinoma: current evidence. Int J
Nephrol Renovasc Dis. 2014;7:401–7.
8. NCCN. Clinical practice guidelines in oncology. Kidney Cancer, Version 2.
2019. https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf.
Accessed 3 Jan 2019.
9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in
metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

Page 14 of 15

10. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or
metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin
Oncol. 2010;28:1061–8.
11. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic
renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31.
12. MacLean E, Mardekian J, Cisar LA, Hoang CJ, Harnett J. Real-world
treatment patterns and costs for patients with renal cell carcinoma
initiating treatment with sunitinib and pazopanib. J Manag Care Spec
Pharm. 2016;22(8):979–90.
13. Clark JI, Wong MK, Kaufman HL, et al. Impact of sequencing targeted
therapies with high-dose interleukin-2 immunotherapy: an analysis of
outcome and survival of patients with metastatic renal cell carcinoma from
an on-going observational IL-2 clinical trial: PROCLAIMSM. Clin Genitourin
Cancer. 2017;15(1):31–41.e4.
14. Miller LA, Stemkowski S, Saverno K, et al. Patterns of care in patients with
metastatic renal cell carcinoma among a U.S. payer population with
commercial or Medicare advantage membership. J Manag Care Spec
Pharm. 2016;22(3):219–26.
15. Vogelzang NJ, Pal SK, Ghate SR, et al. Real-world economic outcomes
during time on treatment among patients who initiated sunitinib or
pazopanib as first targeted therapy for advanced renal cell carcinoma: a
retrospective analysis of Medicare claims data. J Manag Care Spec Pharm.
2018;24:525–33.
16. Rao A, Wiggins C, Lauer RC. Survival outcomes for advanced kidney cancer
patients in the era of targeted therapies. Ann Transl Med. 2018;6:165.
17. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity
index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–67.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use
with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.
19. TORISEL. (temsirolimus) [package insert]. Philadelphia, PA: Wyeth
Pharmaceuticals Inc.; 2017.
20. AFINITOR (everolimus) [package insert]. East Hanover. NJ: Novartis
Pharmaceuticals Corporation; 2017.
21. Avastin (bevacizumab) [summary of product characteristics]. GrenzachWyhlen. Germany: Roche Registration GmbH; 2016.
22. INLYTA (axitinib) [package insert]. New York, NY: Pfizer Laboratories; 2014.
23. VOTRIENT (pazopanib) [package insert]. East Hanover. NJ: Novartis
Pharmaceuticals Corporation; 2017.
24. NEXAVAR (sorafenib) [package insert]. Wayne. NJ: Bayer HealthCare
Pharmaceuticals Inc.; 2015.
25. SUTENT (sunitinib) [package insert]. New York, NY: Pfizer Laboratories; 2017.
26. Jonasch E, Signorovitch JE, Lin PL, et al. Treatment patterns in
metastatic renal cell carcinoma: a retrospective review of medical
records from US community oncology practices. Curr Med Res Opin.
2014;30(10):2041–50.
27. Harshman LC, Srinivas S. The bevacizumab experience in advanced renal
cell carcinoma. Onco Targets Ther. 2010;3:179–89.
28. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an
anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
N Engl J Med. 2003;349(5):427–34.
29. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of
erlotinib combined with bevacizumab compared with bevacizumab alone
in metastatic renal cell cancer. J Clin Oncol. 2007;25(29):4536–41.
30. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both
for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.
31. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced
renal cell carcinoma: a double-blind, randomised, placebo-controlled phase
III trial. Lancet. 2008;372(9637):449–56.
32. Feinberg BA, Jolly P, Wang ST, et al. Safety and treatment patterns of
angiogenesis inhibitors in patients with metastatic renal cell carcinoma:
evidence from US community oncology clinics. Med Oncol. 2012;29:786–94.
33. Hess G, Borker R, Fonseca E. Treatment patterns: targeted therapies
indicated for first-line management of metastatic renal cell carcinoma in a
real-world setting. Clin Genitourin Cancer. 2013;11:161–7.
34. Schmidinger M. Understanding and managing toxicities of vascular
endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11(2):172–91.
35. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of
targeted anticancer therapies. CA Cancer J Clin. 2013;63(4):249–79.
36. Ravaud A. Treatment-associated adverse event management in the
advanced renal cell carcinoma patient treated with targeted therapies.
Oncologist. 2011;16(suppl 2):32–44.

Pal et al. BMC Cancer

(2019) 19:548

37. Pal SK, Figlin RA. Treatment options in metastatic renal cell carcinoma: focus
on mTOR inhibitors. Clin Med Insights Oncol. 2010;4:43–53.
38. Nishino M, Tirumani SH, Ramaiya NH, Hodi FS. Cancer immunotherapy and
immune-related response assessment: the role of radiologists in the new
arena of cancer treatment. Eur J Radiol. 2015;84(7):1259–68.
39. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of
nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin
Oncol. 2013;31(34):4311–8.
40. Harrison MR, Hirsch BR, George DJ, et al. Real-world outcomes in metastatic
renal cell carcinoma: insights from a joint community-academic registry. J
Oncol Pract. 2014;10(2):e63–72.
41. Beisland C, Johannesen TB, Klepp O, et al. Overall survival in renal cell
carcinoma after introduction of targeted therapies: a Norwegian
population-based study. Onco Targets Ther. 2017;10:371–85.
42. OPDIVO (nivolumab) [package insert]. Princeton. New Jersey: Bristol-Myers
Squibb Company; 2018.
43. YERVOY. (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb
Company; 2018.
44. COMETRIQ. (cabozantinib) [package insert]. Alameda, CA: Exelixis, Inc.; 2018.

Page 15 of 15

